Status:
ACTIVE_NOT_RECRUITING
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Guangdong Provincial People's Hospital
Guangdong Provincial Hospital of Traditional Chinese Medicine
Conditions:
Colorectal Cancer
Microsatellite Instability High
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) for dMMR/MSI-H colorectal cancer staged as lo...
Detailed Description
This is an open-label phase II study, with the aim of determining the efficacy of PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) as a neoadjuvant therapy for dMMR/MSI-H locally advanced...
Eligibility Criteria
Inclusion
- Locally confirmed dMMR or MSI-H colorectal carcinoma
- Tumor staging based on CT/MR or transrectal ultrasound imaging:
- Colon cancer: radiological high risk (rT4 or rT3 tumour with extramural extension ≥ 5mm with or without lymph node involvement)
- Rectal cancer: \<12 cm from the anal verge and radiological high risk (rT3/4 with or without lymph node involvement)
- No sign of bowel obstruction, or bowel obstruction has been relieved by ostomy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to study start
- Aged 18 or over
- Life expectancy of at least 2 years
- Measurable disease
- Female participants of childbearing potential must be willing to use adequate contraception for the course of the study starting with the first dose of study medication through 120 days after the last PD-1 antibody dose
- Male participants must agree to use adequate contraception for the course of the study starting with the first dose of study medication through 120 days after the last PD-1 antibody dose
- Adequate organ function
Exclusion
- Active autoimmune disease that has required systemic treatment in past 2 years
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to this study start
- Currently participating and receiving treatment in another study within 4 weeks of study start
- History of severe allergic reaction to monoclonal antibody
- Strong evidence of distant metastases or peritoneal nodules (M1)
- Colonic obstruction that has not been defunctioned
- Has received prior therapy with an immune checkpoint inhibitor (e.g., anti-programmed cell death \[PD\]-1, anti-PD ligand 1 \[L1\], anti-PD-L2 agent, or anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] agent, etc.) or anti-VEGF agents (e.g., Bevacizumab, Apatinib)
- Any other malignant disease within the preceding 5 years with the exception of non-melanomatous skin cancer, carcinoma in situ and early stage disease with a recurrence risk \<5%
- Received a live vaccine within 30 days of planned start of study medication
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or C
- Known history of, or any evidence of interstitial lung disease or active, non-infectious pneumonitis
- Known history of active tuberculosis (Bacillus tuberculosis \[TB\])
- Active infection requiring systemic therapy
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04715633
Start Date
December 1 2020
End Date
July 31 2025
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
651 Dongfeng Road East
Guangzhou, Guangdong, China, 510060